[Treatment for CKD-MBD(Chronic Kidney Disease-Mineral and Bone Disorder)].

Clinical calcium Pub Date : 2016-02-01
Yuko Iwashita, Yu Iwashita, Takafumi Ito, Takashi Shigematsu
{"title":"[Treatment for CKD-MBD(Chronic Kidney Disease-Mineral and Bone Disorder)].","authors":"Yuko Iwashita, Yu Iwashita, Takafumi Ito, Takashi Shigematsu","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>CKD is a common disease that is estimated to develop one in eight persons in Japan. The CKD itself is highly risk factor on the cardiac/vascular mortality. In addition,a new concept has been proposed \"CKD-MBD\". CKD-MBD is composed of a combination of abnormal mineral metabolism, abnormal bone, and extra skeletal calcification with cardiovascular high mortality. Treatment for CKD-MBD is a wide-ranging. We aim to decline cardiovascular event, fracture, and mortality rate of patients with CKD. The main therapeutic target for CKD-MBD becomes the phosphate control. Today, we can use of the VRDA, Calcimimetics and muti-phosphate binders as a lot of pharmacological intervention.</p>","PeriodicalId":502100,"journal":{"name":"Clinical calcium","volume":"26 2","pages":"259-67"},"PeriodicalIF":0.0000,"publicationDate":"2016-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical calcium","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

CKD is a common disease that is estimated to develop one in eight persons in Japan. The CKD itself is highly risk factor on the cardiac/vascular mortality. In addition,a new concept has been proposed "CKD-MBD". CKD-MBD is composed of a combination of abnormal mineral metabolism, abnormal bone, and extra skeletal calcification with cardiovascular high mortality. Treatment for CKD-MBD is a wide-ranging. We aim to decline cardiovascular event, fracture, and mortality rate of patients with CKD. The main therapeutic target for CKD-MBD becomes the phosphate control. Today, we can use of the VRDA, Calcimimetics and muti-phosphate binders as a lot of pharmacological intervention.

[CKD-MBD(慢性肾脏-矿物质和骨骼疾病)的治疗]。
慢性肾病是一种常见病,据估计在日本每8个人中就有1人患病。CKD本身是心脏/血管死亡的高危因素。此外,还提出了一个新的概念“CKD-MBD”。CKD-MBD是由矿物质代谢异常、骨骼异常和额外骨骼钙化共同组成的,心血管死亡率高。CKD-MBD的治疗范围广泛。我们的目标是降低慢性肾病患者的心血管事件、骨折和死亡率。CKD-MBD的主要治疗靶点成为磷酸盐控制。今天,我们可以使用VRDA,石灰化剂和多磷酸盐结合剂作为许多药物干预。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信